Serologicals — Investor Presentation (January 2006)
28 slides from Serologicals's investor presentation, Jan 10, 2006
Slide 1: 2006 Guidance
Serologicals: Corporation 2006 Guidance building value, enhancing lives January 2006
Slide 2: Safe Harbor Statement
Serologicals Safe Harbor Chen: This presentation may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding industry trends, the Company's growth prospects and product development plans
Slide 3: Pro Forma Disclosure Comment
Serologicals Pro Forma Disclosure Comment Corporation This presentation will include discussion of “non-GAAP financial measures” as that term is defined in Regulation G. For actual results, the most directly comparable GAAP financial measures and information reconciling these non-GAAP financial meas
Slide 4: Today's Overriding Message
Serologicals Today’s Overriding Message Coes” * Serologicals is a high-growth company that consistently outperforms its peers and markets ¢ Our strategy: - Focus on select, high-growth markets where Serologicals can achieve and strengthen its leadership position - Sustain leadership in product devel
Slide 5: Our Business Model
Our Business Model 2. Develop “best in class” products / tools / services — internal = acquisitions = licensing / collaborations 1. pe ae 3. Leverage infrastructure select markets — sales force — research — R&D — bioprocessing — facilities 4. Kecu HGR growth, high margins, high shareowner value
Slide 6: Serologicals in Action - A New Company
Serologicals Serologicals in Action - ANew Company “ertion Last 5 years Number of acquisitions <>» Amount invested in >$400M acquisitions & infrastructure “ R&D staff additions ——€ 150+ >) Commercial staff additions F 165 (includes customer service & technical support) x4 if FA By
Slide 7: The Foundation for Continued Success
The Foundation for Continued Success Serologicals Corporation 60% Research e Broad portfolio and customer base e ~ 11,000 products © Proprietary * 70% revenues © Leadership in: ~ Kinases - Neuroscience - Stem cell research - Nuclear function ~ Antibodies ¢ Pioneer of kinase selectivity screening ser
Slide 8: Extraordinary Financial Performance
Extraordinary Financial Performance Revenues ($M) $54 U 03 + Midpoint of guidance range 04 0s Guidancett) Pro forma EPS Continuing Operations ($) z 94 $0.79 $0.71 $0.38 $033 Tt 04 catsarcat
Slide 9: Impressive Organic Growth
Serologicals Impressive Organic Growth Corporation Strong and Sustainable Organic Growth of 15% () Key Drivers of Organic Growth e Highest new product development and commercialization productivity in the industry e Sustaining leadership Kinase profiling and assays Nuclear function Stem cells Drug d
Slide 10: 2005 in Review
Serologicals 2005 in Review
Slide 11: 2005 Guidance Reaffirmed
2005 Guidance Reaffirmed Revised 2005 Guidance 13% ‘organic growth Revenue $265.0 - $270.0M G Bea “) wi G growth Pro forma EPS $0.92 - $0.95 . Gp We Plan to Meet or Exceed 2005 Guidance
Slide 12: Key Accomplishments in 2005
Serologicals Key Accomplishments in 2005 oa ¢ Introduced innovative products and broadened product portfolio - Expanded kinase assays and panel offerings - Introduced Onco-CYTE™ to the EX-CYTE® franchise - Acquired UCOE gene expression technology ¢ Increased value of new products released through ki
Slide 13: The Results in 2005 - Superior Growth
Serologicals The Results in 2005 - Superior Growth —“*reration ¢ With a 13% organic growth rate in 2005, we have outperformed the industry: - Global total market for research products growth rate of 5%-6% - NIH funding relatively flat - Pharma pre-clinical expenditures growth rate of ~ 15% - Total c
Slide 14: 2006 Outlook
2006 Outlook
Slide 15: 2006 Guidance
2006 Guidance Continue High Revenue and Earnings Growth 2005 Guidance 2006 Guidance Gr Pro Forma Pro Forma ow Revenue $265-270 Million | $295-$305 Million 11%-13% Earnings Per Share $0.92-$0.95 $1.12-$1.16 22% Capital $15 Million $23 Million Expenditures EBITDA $62-$65 32%-34%
Slide 16: Key Initiatives in 2006
geckos Corporation Key Initiatives in 2006
Slide 17: Research Segment
Serologicals Research Segment Corporation e Focus on drug discovery and new platforms - Expand leadership positions in current drug discovery target offering and identify new ones (e.g., kinases, GPCRs, HDACs, phosphatases) - Identify promising new platforms/technologies that enable our customers to
Slide 18: Bioprocessing Segment
Serologicals Bioprocessing Segment Corporation ¢ Focus on delivering superior service - Dedicate continual resources to our EX-CYTE® customers - Streamline customer distribution process ¢ Continue to strengthen our product portfolio - Develop new products: * Animal-free EX-CYTE® * Recombinant human
Slide 19: Acquisition Strategy
r Acquisition Strategy e Short term: identify additional opportunities in high-growth markets to fill gaps or enter adjacent markets * Long term: identify opportunities to increase scale and portfolio diversification ¢ All transactions must be accretive
Slide 20: Plant Rationalization Decisions
Plant Rationalization Decisi e We are dedicated to seizing opportunities to reduce expenses and redundancies without compromising our customers’ expectations - Lake Placid Transition ~ Toronto Plans — Lawrence Plans
Slide 21: Lake Placid Transition Update
Lake Placid Transition Update Plan * Streamlined R&D and administrative functions to Temecula ¢ Transfer all manufacturing operations H1 2006 * Proceed with personnel transfers/replacements as planned Benefits ¢ Scientific expertise concentrated in a single location ¢ Leverages supply chain manageme
Slide 22: Toronto Plans
onto Plans Plan * Transition all BSA production and other enzyme products to Kankakee in 1H 2006 * Write down plant to net realizable value in Q4 2005 - Book Value: $17 Million - Closure Costs: $2-$3 Million Benefits « Avoids $6-8 Million in cap ex spending required for upgrades e Improves gross mar
Slide 23: EX-CYTE Update
Serologicals YYTE® Update Corporation *° EX-CYTE® demand continues as expected - 4 FDA approved products - 2 Phase III products - 25+ Early stage projects « Kankakee capacity increased by 50% in 2005 - Process improvements streamline and de-bottleneck production - Margins improve by 400-500 basis po
Slide 24: Lawrence Plans
wrence Plans Plan Benefits * Write down plant to net * Meets expanding EX- realizable value in Q4 2005 CYTE® customer (NBV: $33 Million) demand e Prepare facility for sale ¢ Continues to improve - Cost of closure: $3 - $4 gross margins Million ¢ Improves customer ¢ Continue to identify margin servic
Slide 25: Investing for the Future
Serologicals Investing for the Future Cope” E-Commerce & Com) Other IS Projects Temecula Expansion Kankakee Expansion © s7.0" > & Conversion Projects Dundee Cem) Capacity Additions Maintenance © $5.0M ») Total —————_________+ C s23.0m >
Slide 26: Other Financial Metrics for 2006
Serologicals* Other Financial Metrics for 2006 Corporation jancial Metrics * Free cash flow - $40 Million up 25% * DSO — Improve to 55 days outstanding from 60 days + Return on net assets - 15% + * Stock option expense - $0.04-$0.06 or $3.3 Million pre-tax
Slide 27: 2005 Quarterly Results
2005 Quarterly Results 2005 Results Revenue Pro Forma EPS aul Ql 21% 14% Q2 24% 20% —_ Q3 25% 29% =] a4 30% 37% Uses midpoint of 2005 guidance
Slide 28: Searchable text section of graphics shown above
Searchable text section of graphics shown above 2 006 Guidance [LOGO] [GRAPHIC] building value, enhancing lives January 2006 [ L OGO] Safe Harbor This presentation may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, wit